XML 63 R42.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation (Details) - USD ($)
12 Months Ended
Jan. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Number of Shares      
Outstanding at beginning of the period   352,282 353,565
Granted   810,000 0
Exercised   (48,435)  
Forfeited   (2,381) (1,283)
Outstanding at end of the period   1,111,466 352,282
Exercisable at end of period   1,061,466  
Weighted Average Exercise Price      
Outstanding at beginning of the period (in dollars per share)   $ 0.19 $ 0.19
Granted (in dollars per share)   3.46  
Exercised (in dollars per share)   0.19  
Forfeited (in dollars per share)   0.14 0.14
Outstanding at end of the period (in dollars per share)   2.57 $ 0.19
Exercisable at end of period (in dollars per share)   $ 2.54  
Weighted Average Remaining Contractual Term      
Outstanding at end of the period (in years)   8 years 4 months 24 days  
Exercisable at end of period (in years)   8 years 3 months 18 days  
Additional disclosures      
Aggregate intrinsic value of options outstanding   $ 5,523,826  
Aggregate intrinsic value of options exercisable   $ 5,303,326  
Weighted average grant date fair value   $ 2.19  
Share-based compensation expense, including stock issued to consultants and advisors   $ 1,864,913 $ 8,483
Research and Development Expense      
Additional disclosures      
Share-based compensation expense, including stock issued to consultants and advisors   $ 138,704 $ 0
One year vesting period      
Number of Shares      
Granted   50,000  
Consultants and advisors      
Additional disclosures      
Number of shares issued to consultants and advisors   25,000 0
Fair value of stock awards granted   $ 122,750  
Unrecognized compensation expense   $ 0  
Stock Options      
Estimated fair value of options      
Risk-free interest rate   0.38%  
Expected life   5 years  
Expected volatility   80.00%  
Expected dividend yield   0.00%  
Additional disclosures      
Term of award   10 years  
Unrecognized compensation expense   $ 31,970  
Weighted-average recognition period   3 months 18 days  
2019 Plan      
Additional disclosures      
Shares authorized 1,000,000    
Shares available for future grants   168,664  
2019 Plan | Stock Options      
Additional disclosures      
Term of award 10 years    
2018 Plan | Stock Options      
Number of Shares      
Outstanding at end of the period 352,282    
Additional disclosures      
Shares available for future grants 0